MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Merrimack Pharmaceuticals, Inc.

One Kendall Square
Suite B7201
Cambridge, MA 02139
United States
617-441-1000
http://www.merrimack.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard PetersPres, CEO & Director1.34MN/A1963
Ms. Jean M. FranchiCFO & Treasurer576.33kN/A1966
Dr. Anthony J. SinskeyCo-Founder and Scientific AdvisorN/AN/A1940
Mr. Jeffrey A. MunsieGen. Counsel, Head of Corp. Operations & Sec.N/AN/A1977
Geoffrey Grande C.F.A.Sr. Director of CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Merrimack Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.